VBX-1000 (MIV-701) is the first specific cathepsin-K inhibitor, for the treatment of periodontal disease in dogs. During the early development of a selective cathepsin-K inhibitor, MIV-701 was discovered to have properties suitable for non-human animal use and it was out-licensed to Vetbiolix in 2019 to explore clinical utility in non-human animal.
In the study conducted by Vetbiolix, the drug was well tolerated and the primary efficacy endpoint was met, achieving a statistically significant reduction of the plasma biomarker for bone degradation (CTX1). Vetbiolix is now working with experts in the field to set up a regulatory Pilot clinical study to further strengthen the demonstration of the effects of VBX-1000 (MIV-701) in a double blind, randomized, placebo-controlled clinical trial in dogs.
As part of the agreement with Vetbiolix,
- "Partnering and collaborations are important parts of
For additional information, please contact;
Telephone: +46 8 5468 3100.
E-mail: magnus.christensen@medivir.com
About
About Vetbiolix
Vetbiolix develops innovative products for the treatment and prevention of diseases affecting pets. Vetbiolix has built a unique pipeline of First-in-class small molecules in-licensed (exclusive and worldwide license) from Human Biotech worldwide which will answer to veterinary unmet medical needs in periodontitis, osteoarthritis and gut motility disorders. Vetbiolix focuses exclusively on clinical developments of its drug candidates: the company invests on (i) clinical proof of concept studies, (ii) CMC-Pharmaceutical developments, (iii) regulatory Pilot clinical studies and (iv) regulatory Pivotal clinical studies. Revenue generation of the company will be based on out-licensing and/or co-developments deals with the Veterinary Pharmaceutical Industry. www.vetbiolix.com
https://news.cision.com/medivir/r/medivir-s-partner-vetbiolix-announces-positive-results-from-proof-of-concept-study-with-vbx-1000--pr,c3961646
https://mb.cision.com/Main/652/3961646/2731714.pdf
(c) 2024 Cision. All rights reserved., source